This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Syndulko, K. Articles by Tourtellotte, W. W Search for Related Content PubMed Articles by Syndulko, K. Articles by Tourtellotte, W. W Social Bookmarking                         What's this?

Comparative evaluations of neuroperformance and clinical outcome assessments in chronic progressive multiple sclerosis: I. reliability, validity and sensitivity to disease progression

Neurology Service, VA Medical Center — West Los Angeles

Dershin Ke

Present address: Department of Medicine, Show Chwen Memorial Hospital, Chang-Hua, Taiwan

George W Ellison

Department of Neurology, UCLA School of Medicine, Los Angeles, California, USA

Robert W Baumhefner

Department of Neurology, UCLA School of Medicine, Los Angeles, California, USA

Lawrence W Myers

Department of Neurology, UCLA School of Medicine, Los Angeles, California, USA

Wallace W Tourtellotte

Present address: Department of Medicine, Show Chwen Memorial Hospital, Chang-Hua, Taiwan

There remains controversy regarding the most sensitive and valid outcome assessments to use in multiple sclerosis (MS) clinical trials. A double blind, placebo controlled, parallel group multicenter clinical trial to evaluate the clinical efficacy of cyclosporine A in chronic progressive MS incorporated several major clinical and performance outcome assessment modalities and a large sample size, both of which provide a unique opportunity to explore the relationship among MS disease status and the various outcome measures over time. The measures included a structured neurological examination, the Kurtzke Functional System scales and Expanded Disability Status Score, and the Incapacity Status Scale from the MS Minimal Record of Disability, die Harvard Ambulation Index, and neuroperformance testing. A test-retest reliability index, principal component analyses and a signal-to-noise ratio metric were used to comparatively evaluate the reliability, validity and sensitivity to disease progression of the various outcome assessments. The goal was to provide a rational basis for selection of behavioral outcome assessments in future MS clinical trials by identifying the primary dimensions of MS measured by the candidate outcome assessments and providing an objective basis for selecting tests that are most sensitive to MS disease and its progression over a two year trial period. We conclude that the components of the major clinical and performance measures show excellent reliability and cross validation. Principal component analyses of all outcome assessments yielded six primary underlying factors for describing disease status in chronic progressive MS that included lower extremity/pyramidal dysfunction, cerebellar/brainstem and upper extremity dysfunction, somatosensory dysfunction, visual dysfunction, mental or intellectual dysfunction and bowel/bladder problems. Signal-to-noise ratios indicated that upper and lower extremity composites of neuroperformance test kerns provided the most sensitive indicators of MS disease progression in the placebo group over the 2 year trial period.

Key Words: neuroperformance • multiple sclerosis • clinical trial • outcome assessment • statistical analysis

Multiple Sclerosis, Vol. 2, No. 3, 142-156 (1996)
DOI: 10.1177/135245859600200305


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M E Morris, C Cantwell, L Vowels, and K Dodd Changes in gait and fatigue from morning to afternoon in people with multiple sclerosis J. Neurol. Neurosurg. Psychiatry, March 1, 2002; 72(3): 361 - 365. [Abstract] [Full Text] [PDF]

				G V McDonnell and S A Hawkins An assessment of the spectrum of disability and handicap in multiple sclerosis: a population-based study Multiple Sclerosis, April 1, 2001; 7(2): 111 - 117. [Abstract] [PDF]

				J S Fischer, R A Rudick, G R Cutter, S C Reingold, and National MS Society Clinical Outcomes Assessment T The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment Multiple Sclerosis, August 1, 1999; 5(4): 244 - 250. [Abstract] [PDF]

				G. R. Cutter, M. L. Baier, R. A. Rudick, D. L. Cookfair, J. S. Fischer, J. Petkau, K. Syndulko, B. G. Weinshenker, J. P. Antel, C. Confavreux, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure Brain, May 1, 1999; 122(5): 871 - 882. [Abstract] [Full Text] [PDF]